| 1 | Liver stiffness: a novel parameter for the diagnosis of live… (10.2147/hmer.s7394) | Abstract References ORCID | 189.57 | 336 |
| 2 | Hepatitis C infection in Egypt: prevalence, impact and manag… (10.2147/hmer.s113681) | Abstract References ORCID | 155.39 | 117 |
| 3 | Transmission, diagnosis, and management of hepatitis E: an u… (10.2147/hmer.s63417) | Abstract References ORCID | 147.64 | 92 |
| 4 | Autophagy: a new target for nonalcoholic fatty liver disease… (10.2147/hmer.s98120) | Abstract References ORCID | 144.32 | 83 |
| 5 | The pathophysiology of thrombocytopenia in chronic liver dis… (10.2147/hmer.s74612) | Abstract References ORCID | 140.19 | 73 |
| 6 | PNPLA3 expression and its impact on the liver: current persp… (10.2147/hmer.s125718) | Abstract References ORCID | 136.47 | 65 |
| 7 | Hepatocellular carcinoma: current trends in worldwide epidem… (10.2147/hmer.s16316) | Abstract References ORCID | 135.46 | 63 |
| 8 | Progressive familial intrahepatic cholestasis: diagnosis, ma… (10.2147/hmer.s137209) | Abstract References ORCID | 134.95 | 62 |
| 9 | Daclatasvir–sofosbuvir combination therapy with or… (10.2147/hmer.s62014) | Abstract References ORCID | 130.53 | 54 |
| 10 | Tyrosine levels are associated with insulin resistance in pa… (10.2147/hmer.s79100) | Abstract References ORCID | 128.70 | 51 |
| 11 | Interferon-free combination therapies for the treatment of h… (10.2147/hmer.s55864) | Abstract References ORCID | 124.71 | 45 |
| 12 | Hepatic encephalopathy: current challenges and future prospe… (10.2147/hmer.s118964) | Abstract References ORCID | 120.15 | 39 |
| 13 | Presence and consequence of tooth periapical radiolucency in… (10.2147/hmer.s113485) | Abstract References ORCID | 119.33 | 38 |
| 14 | Obeticholic acid for the treatment of primary biliary cholan… (10.2147/hmer.s91709) | Abstract References ORCID | 118.48 | 37 |
| 15 | Decline in HAV-associated fulminant hepatic failure and live… (10.2147/hmer.s22309) | Abstract References ORCID | 115.81 | 34 |
| 16 | Autophagy in hepatocellular carcinomas: from pathophysiology… (10.2147/hmer.s63700) | Abstract References ORCID | 115.81 | 34 |
| 17 | Unresectable hepatoblastoma: current perspectives (10.2147/hmer.s89997) | Abstract References ORCID | 115.81 | 34 |
| 18 | Reversal of hepatic fibrosis: pathophysiological basis of an… (10.2147/hmer.s9051) | Abstract References ORCID | 115.81 | 34 |
| 19 | Idiopathic noncirrhotic portal hypertension: current perspec… (10.2147/hmer.s85544) | Abstract References ORCID | 114.86 | 33 |
| 20 | <p>Lysosomal acid lipase deficiency – early diagnosis… (10.2147/hmer.s201630) | Abstract References ORCID | 111.85 | 30 |
| 21 | Transarterial chemoembolization with drug-eluting beads vers… (10.2147/hmer.s105395) | Abstract References ORCID | 108.54 | 27 |
| 22 | Management of refractory cirrhotic ascites: challenges and s… (10.2147/hmer.s136578) | Abstract References ORCID | 108.54 | 27 |
| 23 | Pharmacogenetics of hepatitis C: transition from interferon-… (10.2147/hmer.s41127) | Abstract References ORCID | 108.54 | 27 |
| 24 | <p>Impact of chronic schistosomiasis and HBV/HCV co-in… (10.2147/hmer.s155962) | Abstract References ORCID | 104.85 | 24 |
| 25 | Persistence of immunity from 1 year of age after one or two… (10.2147/hmer.s33847) | Abstract References ORCID | 102.13 | 22 |
| 26 | Spontaneous bacterial peritonitis in patients with cirrhosis… (10.2147/hmer.s164250) | Abstract References | 100.85 | 103 |
| 27 | Direct comparison of the FibroScan XL and M probes for asses… (10.2147/hmer.s45234) | Abstract References ORCID | 99.17 | 20 |
| 28 | Rifaximin in the treatment of hepatic encephalopathy (10.2147/hmer.s11988) | Abstract References ORCID | 97.58 | 19 |
| 29 | Impact of hepatitis C virus genotype-4 eradication following… (10.2147/hmer.s142600) | Abstract References ORCID | 95.91 | 18 |
| 30 | Transarterial chemoembolization using iodized oil for unrese… (10.2147/hmer.s31440) | Abstract References ORCID | 95.91 | 18 |
| 31 | Inhibition of Notch signaling affects hepatic oval cell resp… (10.2147/hmer.s12368) | Abstract References ORCID | 94.15 | 17 |
| 32 | Treatment of nonalcoholic steatohepatitis with vitamins E an… (10.2147/hmer.s41258) | Abstract References ORCID | 94.15 | 17 |
| 33 | Acute pediatric hyperammonemia: current diagnosis and manage… (10.2147/hmer.s140711) | Abstract References | 90.65 | 64 |
| 34 | Role of intrafamilial transmission in high prevalence of hep… (10.2147/hmer.s129681) | Abstract References ORCID | 90.31 | 15 |
| 35 | Effect of sitagliptin on hepatic histological activity and f… (10.2147/hmer.s158053) | Abstract References | 90.31 | 63 |
| 36 | A high prevalence of extreme hyperferritinemia in acute hepa… (10.2147/hmer.s4393) | Abstract References ORCID | 90.31 | 15 |
| 37 | Sofosbuvir for the treatment of chronic hepatitis C: between… (10.2147/hmer.s44375) | Abstract References ORCID | 90.31 | 15 |
| 38 | Diagnosis and staging of fibrosis in patients with chronic h… (10.2147/hmer.s125234) | Abstract References ORCID | 88.21 | 14 |
| 39 | Overt hepatic encephalopathy in Italy: clinical outcomes and… (10.2147/hmer.s87594) | Abstract References ORCID | 85.96 | 13 |
| 40 | Clinical applications of the Model for End-Stage Liver Disea… (10.2147/hmer.s9049) | Abstract References ORCID | 83.55 | 12 |
| 41 | <p>Portosystemic shunts and refractory hepatic encepha… (10.2147/hmer.s169024) | Abstract References | 82.17 | 43 |
| 42 | <p>A Review Of Current And Upcoming Treatment Modaliti… (10.2147/hmer.s188991) | Abstract References | 81.67 | 42 |
| 43 | Ending hepatitis C in the United States: the role of screeni… (10.2147/hmer.s40940) | Abstract References ORCID | 80.94 | 11 |
| 44 | Metabolic syndrome in chronic hepatitis C infection: does it… (10.2147/hmer.s60083) | Abstract References ORCID | 80.94 | 11 |
| 45 | Optimal management of hepatorenal syndrome in patients with… (10.2147/hmer.s6918) | Abstract References ORCID | 80.94 | 11 |
| 46 | Biomarkers for hepatocellular carcinoma: diagnostic and ther… (10.2147/hmer.s50161) | Abstract References ORCID | 78.10 | 10 |
| 47 | Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regi… (10.2147/hmer.s72429) | Abstract References ORCID | 78.10 | 10 |
| 48 | <p>Severe alcoholic hepatitis: current perspectives<… (10.2147/hmer.s197933) | Abstract References | 75.26 | 31 |
| 49 | The role of eltrombopag in the management of hepatitis C vir… (10.2147/hmer.s27100) | Abstract References ORCID | 75.00 | 9 |
| 50 | Management options in decompensated cirrhosis (10.2147/hmer.s62463) | Abstract References ORCID | 75.00 | 9 |